SCHEMBL15420728

SCHEMBL15420728

Cc1cnn(-c2ccc(OC[C@H]3CCOC[C@@H]3NS(C)(=O)=O)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT5 Q92993 1/20 0.38
CHRM1 P11229 2/20 0.37
HRH3 Q9Y5N1 1/20 0.35
HCRTR2 O43614 5/20 0.34
RIPK2 O43353 2/20 0.34
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
FLT3 P36888 1/20 0.33
AURKB Q96GD4 1/20 0.33
INSR P06213 3/20 0.33
ALK Q9UM73 2/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
GCGR P47871 1/20 0.32
HCRTR1 O43613 1/20 0.31
ACACB O00763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420734 0.91 KAT5 (0.39) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15420469 0.90 CHRM1 (0.35) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15420779 0.88 GCGR (0.38) CHRM1HRH3HCRTR2FLT3GCGR
SCHEMBL15420735 0.86 KAT5 (0.38) KAT5CHRM1HCRTR2INSRALK
SCHEMBL15420102 0.85 KAT5 (0.38) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15419964 0.85 KAT5 (0.38) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15420129 0.85 KAT5 (0.38) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15441158 0.84 KAT5 (0.38) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15420145 0.84 KAT5 (0.38) KAT5CHRM1HRH3HCRTR2RIPK2
SCHEMBL15420318 0.83 CHRM1 (0.35) KAT5CHRM1HRH3HCRTR2RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 KAT5 2329/4885CHRM1 227/4885HRH3 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.